Ivantis' eyelash-sized eye stent helped lower intraocular pressure in patients who have undergone cataract surgery after one year, data that could help the company convince the FDA of its device's ...

Twenty-nine patients had the Hydrus stent placed without cataract surgery to assess whether the stent would be effective on its own. No significant complications occurred in either patient group.

The Hydrus stent is 8 mm long. In comparison, ... The iStent has given surgeons and patients another alternative, with no more risk to the eye than cataract surgery, Wiley said.

Eyes that were treated with the Hydrus microstent, which is designed to lower eye pressure, were less likely than untreated eyes to need subsequent invasive glaucoma surgery (6.4% vs 2.5%; P=0.022 ...

The HORIZON trial, which compared cataract surgery alone with cataract surgery in conjunction with implantation of the Hydrus Microstent (Ivantis, Inc; Irvine, California), concluded at 3 years ...

RELATED: Alcon pulls eye micro-stent from market after new 5-year safety data The FDA’s approval for the Hydrus device came the same month Alcon began a voluntary recall of all versions of its ...

Norbert Pfeiffer PARIS — The new Hydrus stent from Ivantis provides effective IOP control with a safe, minimally invasive, ab interno procedure, according to one surgeon speaking at the World ...

Key takeaways: The Hydrus microstent is a minimally invasive glaucoma surgery device for IOP lowering. I. Paul Singh, MD, demonstrates how to implant the device following cataract surgery.

Over a 5-year period, the annual rate of progression in vision loss averaged 0.49 dB with surgery alone, compared with 0.26 dB with surgery plus a Schlemm's canal microstent (Hydrus).

The iStent Trabecular Micro-Bypass Stent System, model GTS100R/L, manufactured by Glaukos Corp., is the first device approved for use in combination with cataract surgery to reduce intraocular ...